IRIS
PATRIGNANI, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.426
EU - Europa 10.222
AS - Asia 9.803
SA - Sud America 1.224
Continente sconosciuto - Info sul continente non disponibili 924
AF - Africa 152
OC - Oceania 19
Totale 39.770
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.054
SG - Singapore 3.609
CN - Cina 3.044
UA - Ucraina 1.828
IE - Irlanda 1.433
GB - Regno Unito 1.361
TR - Turchia 1.256
RU - Federazione Russa 1.229
IT - Italia 1.169
BR - Brasile 993
SE - Svezia 906
FR - Francia 831
VN - Vietnam 830
DE - Germania 637
FI - Finlandia 378
IN - India 315
CA - Canada 178
BD - Bangladesh 164
PL - Polonia 157
HK - Hong Kong 137
AR - Argentina 89
MX - Messico 86
ES - Italia 61
ZA - Sudafrica 59
KR - Corea 58
JP - Giappone 57
IQ - Iraq 53
BE - Belgio 47
CZ - Repubblica Ceca 47
SA - Arabia Saudita 41
NL - Olanda 39
ID - Indonesia 35
CO - Colombia 34
EC - Ecuador 34
JM - Giamaica 32
PK - Pakistan 26
UZ - Uzbekistan 23
VE - Venezuela 22
AT - Austria 21
EU - Europa 21
IL - Israele 19
MA - Marocco 19
AE - Emirati Arabi Uniti 18
LT - Lituania 18
CR - Costa Rica 17
IR - Iran 16
PH - Filippine 16
CL - Cile 15
AU - Australia 14
DZ - Algeria 14
PY - Paraguay 14
EG - Egitto 13
KE - Kenya 12
MY - Malesia 12
HN - Honduras 11
PE - Perù 11
JO - Giordania 10
TN - Tunisia 10
AZ - Azerbaigian 9
EE - Estonia 9
OM - Oman 9
GT - Guatemala 8
RO - Romania 8
TT - Trinidad e Tobago 8
UY - Uruguay 7
BY - Bielorussia 6
GR - Grecia 6
KZ - Kazakistan 6
NI - Nicaragua 6
NP - Nepal 6
PS - Palestinian Territory 6
PT - Portogallo 6
BB - Barbados 5
LY - Libia 5
AL - Albania 4
AM - Armenia 4
BO - Bolivia 4
CG - Congo 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
LB - Libano 4
NZ - Nuova Zelanda 4
SN - Senegal 4
TH - Thailandia 4
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
KW - Kuwait 3
PA - Panama 3
PR - Porto Rico 3
SC - Seychelles 3
SV - El Salvador 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BH - Bahrain 2
BN - Brunei Darussalam 2
CU - Cuba 2
CW - ???statistics.table.value.countryCode.CW??? 2
DM - Dominica 2
GA - Gabon 2
HR - Croazia 2
Totale 38.843
Salva come PNG Salva come JPEG
Città #
Singapore 2.461
San Jose 2.088
Jacksonville 1.969
Chandler 1.728
Dublin 1.423
Southend 1.002
Ashburn 939
Dallas 763
Princeton 706
Council Bluffs 700
Izmir 638
Beijing 627
Dearborn 569
Nanjing 494
Los Angeles 393
Cambridge 324
Wilmington 315
Ho Chi Minh City 283
Tongling 270
Santa Clara 248
Hanoi 201
Nanchang 200
Buffalo 198
New York 188
The Dalles 186
Altamura 171
Boardman 162
Chieti 144
Moscow 139
Shenyang 132
Hong Kong 125
Woodbridge 120
Washington 115
Ann Arbor 114
Phoenix 95
São Paulo 94
Hebei 93
Kraków 93
Kimball 92
Munich 92
Tianjin 84
Grevenbroich 83
Jiaxing 75
Kunming 72
Orem 70
Changsha 68
Denver 64
Brooklyn 63
Rome 63
Redondo Beach 61
Chicago 58
Columbus 57
Hangzhou 55
Warsaw 55
San Francisco 54
Hefei 52
Houston 52
Norwalk 52
Seoul 52
Atlanta 51
Montreal 51
Pescara 50
Yakima 50
Jinan 46
Tokyo 45
Brussels 42
Johannesburg 40
Toronto 40
Orange 39
Helsinki 37
Milan 37
Brno 36
Seattle 35
Boston 34
Chennai 33
Kocaeli 31
Guangzhou 30
London 30
Da Nang 29
Mexico City 29
Rio de Janeiro 29
Shanghai 29
St Louis 29
Ningbo 28
Lanzhou 27
Haiphong 26
Zhengzhou 26
Augusta 25
Belo Horizonte 25
Poplar 25
Frankfurt am Main 24
Hải Dương 24
Mount Pleasant 24
Nuremberg 24
San Mateo 24
Mumbai 23
Riyadh 23
Stockholm 23
Manchester 22
Amsterdam 21
Totale 23.200
Salva come PNG Salva come JPEG
Nome #
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 425
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 397
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 365
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 254
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 201
Antithrombotic Agents and Cancer 189
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 182
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 181
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 176
Advances in NSAID development: Evolution of diclofenac products using pharmaceutical technology 175
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 175
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 171
Low-dose Aspirin prevents hypertension and cardiac fibrosis when thromboxane A2 is unrestrained 168
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 166
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. 165
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 164
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 164
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 161
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 160
Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. 158
LA CASCATA DELL'ACIDO ARACHIDONICO 157
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 157
Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting 155
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 152
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 151
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 151
Dysregulation of gene expression in human fetal endothelial cells from gestational diabetes in response to TGF-β1 150
Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action 148
Thromboxane biosynthesis and pulmonary function in cystic fibrosis 145
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 145
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 145
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 144
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 142
Rare SNP rs12731181 in the miR-590-3p Target Site of the Prostaglandin F2α Receptor Gene Confers Risk for Essential Hypertension in the Han Chinese Population. 142
A double-blind randomized study of the anti-platelet effects of low-dose ASA and placebo in patients after myocardial infarction 141
A comparison of low-dose aspirin and dazoxiben as selective inhibitors of thromboxane A2 production in man. 141
Effetto del propranololo e del suo metabolita attivo 4-OH propranololo sui prostanoidi COX-2 derivati e sull’emossigenasi-1 (OH-1) in cellule HUVEC. 141
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases 140
New insights into COX-2 biology and inhibition. 140
Novel insights into the regulation of cyclooxygenase-2 expression by platelet-cancer cell cross-talk. 140
ALTERED RENAL AND PLATELET ARACHIDONIC ACID METABOLISM IN CIRRHOSIS. 139
Platelet activation in patients with colorectal cancer. 139
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 139
Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity 138
[ITALIAN CONSENSUS ON EULAR 2003 RECOMMENDATIONS FOR THE TREATMENT OF KNEE OSTEOARTHRITIS.] 138
Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses. 138
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 137
Induction of prostacyclin by steady laminar shear stress suppresses Tumor Necrosis Factor-alfa biosyntesis via Heme Oxygenase-1 in human endothelial cells. 137
A class of pyrrole derivatives endowed with analgesic/anti-inflammatory activity. 137
Aspirin, platelet inhibition and cancer prevention. 137
Clinical pharmacology of selective COX-2 inhibitors. 136
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 136
Curbing tumorigenesis and malignant progression through the pharmacological control of the wound healing process. 136
Therapeutic targeting of dysregulated cellular communication. 136
Determinants of platelet activation in human essential hypertension. 136
Inflammation and Cancer: From the Development of Personalized Indicators to Novel Therapeutic Strategies 136
Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients 135
Oxidative stress and platelet activation in essential hyperytension 135
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 135
Differential contribution of cycloooxygenase-isozymes to the generation of prostacyclin and prostaglandin E2 by endothelial cells in response to steady laminar shear stress 135
T-type channel blocking properties and antiabsence activity of two imidazo[1,2-b]pyridazine derivatives structurally related to indomethacin. 134
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 134
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 133
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 132
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 132
Aspirin and Cancer 132
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 131
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 131
AMPLIFICATION LOOPS: THROMBOXANE GENERATION. 131
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 131
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. 130
Risk management profile of etoricoxib: An example of personalized medicine 130
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 129
RECOVERY OF THROMBOXANE BIOSYNTHESIS BY ASPIRIN-TREATED PLATELETS IN VITRO: A NOVEL MECHANISM OF ASPIRIN RESISTANCE. 129
Gut microbiota, host gene expression, and aging. 129
Mechanistic and pharmacological issues of aspirin as an anticancer agent 129
Biology and pharmacology of platelet-type 12-lipoxygenase in platelets, cancer cells, and their crosstalk 128
Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. 128
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 128
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 128
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 128
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 128
Role of Platelets in Inflammation and Cancer: Novel Therapeutic Strategies 128
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 128
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 127
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 127
Platelets and extracellular vesicles in cancer: diagnostic and therapeutic implications 127
Editorial: Eicosanoids in Cancer 127
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 126
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 126
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 126
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 126
A SELECTIVE THROMBOXANE-SYNTHASE INHIBITOR, ON PLATELET AND RENAL PROSTAGLANDIN ENDOPEROXIDE METABOLISM 125
Clinical pharmacology of novel selective COX-2 inhibitors. 125
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 124
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 124
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 124
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 124
New antiplatelet approach: inhibiting Pim kinase to reduce constitutive surface expression of thromboxane A2 receptor 123
Usefulness of enzimatic intermediate markers-example of cox-2 inhibition 123
Totale 14.984
Salva come PNG Salva come JPEG
Categoria #
all - tutte 160.439
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.439
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.198 0 0 0 202 122 9 25 103 123 25 192 397
2022/20234.632 374 433 179 589 495 970 291 409 626 55 90 121
2023/20241.827 163 100 131 53 100 456 496 36 7 35 17 233
2024/20254.671 368 638 539 105 104 152 89 383 481 213 545 1.054
2025/202611.348 955 557 1.246 1.366 841 711 1.792 813 1.273 960 590 244
2026/20273.384 435 839 1.020 1.090 0 0 0 0 0 0 0 0
Totale 39.770